Comparative Pharmacology
Head-to-head clinical analysis: KETEK versus SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETEK versus SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH.
KETEK vs SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Telithromycin binds to the 50S subunit of bacterial ribosome, inhibiting protein synthesis by blocking peptide chain elongation.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis. Together, they provide sequential blockade of folate metabolism, leading to bactericidal activity.
Telithromycin 800 mg orally once daily for 7-10 days.
1 double-strength tablet (800 mg sulfamethoxazole/160 mg trimethoprim) orally every 12 hours for most infections; single-strength tablet (400 mg/80 mg) is used for prophylaxis: 1 tablet orally daily.
None Documented
None Documented
Terminal half-life (t½) is 9.8–10.6 hours in young healthy adults, allowing once-daily dosing. In elderly or severe hepatic impairment, t½ may be prolonged.
Sulfamethoxazole: 10-12 hours (prolonged in renal impairment); Trimethoprim: 8-11 hours (prolonged in hepatic impairment).
Primarily fecal (≈70%) via biliary excretion of unchanged drug; renal excretion accounts for ≈13% (mostly unchanged), with additional minor metabolism (<30%).
Sulfamethoxazole: primarily renal (70-90% as unchanged drug and acetylated metabolite); Trimethoprim: renal (50-60% unchanged, rest as metabolites); small biliary/fecal elimination (<5% each).
Category C
Category D/X
Antibiotic, Ketolide
Antibiotic